Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Ovarian Cancer Vaccine in Advanced Ovarian Cancer
NCT03197584Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Feb 2019
- Modality
- DNA Vaccines, Peptide-based Cancer Vaccines, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, ETBX-021, ETBX-051, ETBX-061, GI-4000 in Epithelial Ovarian Cancer (EOC), sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakiceptETBX-021ETBX-051ETBX-061GI-4000
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT03197584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197584.